alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         National Institute on Alcohol Abuse and Alcoholism, Special Emphasis Panel, Member Conflicts SEP.                    

*Date:*                         April 22, 2010.                    

*Time:*                         12 p.m. to 2 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         NIAAA, 5635 Fishers, Rockville, MD 20852.                    

*Contact Person:*                         Lorraine Gunzerath, PhD, MBA, Scientific Review Officer, National Institute on Alcohol Abuse and Alcoholism, Office of Extramural Activities, Extramural Project Review Branch, 5635 Fishers Lane, Room 2121, Bethesda, MD 20892-9304, 301-443-2369,                         *lgunzera@mail.nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.271, Alcohol Research Career Development Awards for Scientists and Clinicians; 93.272, Alcohol National Research Service Awards for Research Training; 93.273, Alcohol Research Programs; 93.891, Alcohol Research Center Grants; 93.701, ARRA Related Biomedical Research and Research Support Awards., National Institutes of Health, HHS)

Dated: February 26, 2010.

Jennifer Spaeth, 

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2010-4586 Filed 3-8-10; 8:45 am]

BILLING CODE 4140-01-M
Exhibit 15

                           Accountants' Acknowledgment

Footstar, Inc.
Mahwah, New Jersey

Board of Directors:

Re:  Registration Statements Numbers 33-20731 and 33-30011 on Form S-8

With respect to the subject registration statement, we acknowledge our awareness
of the use therein of our report dated April 18, 2000 related to our review of
interim financial information.

Pursuant to Rule 436(c) under the Securities Act of 1933, such report is not
considered a part of a registration statement prepared or certified by an
accountant or a report prepared or certified by an accountant within the meaning
of sections 7 and 11 of the Act.

                                                         /s/KPMG LLP

Short Hills, New Jersey
May 15, 2000


                                       19
<partyblock><br><br><div align="center"><b><font size="+1">Bronx Acupuncture Therapy, P.C., a/a/o Shade McBeth, Plaintiff-Appellant, <br><br>against<br><br>Hereford Ins. Co., Defendant-Respondent.</font></b></div><br><br><p>Plaintiff appeals from an order of the Civil Court of the City of New York, New York County (Alexander M. Tisch, J.), entered July 6, 2015, which granted defendant's motion for summary judgment.</p><p>Per Curiam. </p><p>Order (Alexander M. Tisch, J.), entered July 6, 2015, reversed, with $10 costs, and defendant's motion denied.</p><p>This action, seeking recovery of assigned first-party no-fault benefits, is not ripe for summary dismissal. Although defendant claims that the assignor failed to appear for two scheduled independent medical examinations (IMEs), defendant failed to show that the scheduling of the IMEs complied with the procedures and time frames set forth in Insurance Department Regulations (11 NYCRR) ยง 65-3.5(d); <a href="../2015/2015_06762.htm" target="_blank"><i>see American Tr. Ins. Co. v Vance</i>, 131 AD3d 849</a> [2015]; <a href="../2015/2015_06761.htm" target="_blank"><i>American Tr. Ins. Co. v Longevity</i>, 131 AD3d 841</a> [2015];<a href="../2015/2015_50318.htm" target="_blank"><i> Acupuncture, Approach, P.C. v Allstate Ins. Co.</i>, 46 Misc 3d 151</a>[A], 2015 NY Slip Op 50318[U] [App Term, 1st Dept. 2015]). In this regard, there is no indication in the record as to when defendant received plaintiff-provider's no-fault claims and thus no basis to determine the timeliness of defendant's IME requests. Although this issue was raised for the first time on appeal, it presents a question of law which this Court can review (<i>see American Tr. Ins. Co. v Longevity</i>, 131 AD3d at 841-842).</p><p>THIS CONSTITUTES THE DECISION AND ORDER OF THE COURT.</p><br>I concur I concur I concur<br>Decision Date: October 19, 2016<br><br><div align="center"><form method="LINK" action="../../slipidx/at_1_idxtable.shtml"><input type="submit" value="Return to Decision List"></form></div></partyblock>
§ 74.1208 D&C Green No. 8. ( a ) *Identity.* ( 1 ) The color additive D&C Green No. 8 is principally the trisodium salt of 8-hydroxy-1,3,6-pyrene-trisulfonic acid.
( 2 ) Color additive mixtures for use in externally applied drugs made with D&C Green No. 8 may contain only those diluents that are suitable and that are listed in part 73 of this chapter for use in color additive mixtures for coloring externally applied drugs.
( b ) *Specifications.* D&C Green No. 8 shall conform to the following specifications and shall be free from impurities other than those named to the extent that such impurities may be avoided by good manufacturing practices: Volatile matter (at 135 °C), not more than 15 percent. Water-insoluble matter, not more than 0.2 percent. Chlorides and sulfates (calculated as sodium salt), not more than 20 percent. The trisodium salt of 1,3,6-pyrenetrisulfonic acid, not more than 6 percent. The tetrasodium salt of 1,3,6,8-pyrenetetrasulfonic acid, not more than 1 percent. Pyrene, not more than 0.2 percent. Lead (as Pb), not more than 20 parts per million. Arsenic (as As), not more than 3 parts per million. Mercury (as Hg), not more than 1 part per million. Total color, not less than 65 percent.
( c ) *Uses and restrictions.* D&C Green No. 8 may be safely used in externally applied drugs in amounts not exceeding 0.01 percent by weight of the finished product.
( d ) *Labeling.* The label of the color additive and any mixtures prepared therefrom intended solely or in part for coloring purposes shall conform to the requirements of § 70.25 of this chapter.
( e ) *Certification.* All batches of D&C Green No. 8 shall be certified in accordance with regulations in part 80 of this chapter.
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.6050 Ovarian adnexal mass assessment score test system. ( a ) *Identification.* An ovarian/adnexal mass assessment test system is a device that measures one or more proteins in serum or plasma. It yields a single result for the likelihood that an adnexal pelvic mass in a woman, for whom surgery is planned, is malignant. The test is for adjunctive use, in the context of a negative primary clinical and radiological evaluation, to augment the identification of patients whose gynecologic surgery requires oncology expertise and resources.
( b ) *Classification.* Class II (special controls). The special control for this device is FDA's guidance document entitled “Class II Special Controls Guidance Document: Ovarian Adnexal Mass Assessment Score Test System.” For the availability of this guidance document, *see* § 866.1(e).
( c ) *Black box warning.* Under section 520(e) of the Federal Food, Drug, and Cosmetic Act these devices are subject to the following restriction: A warning statement must be placed in a black box and must appear in all advertising, labeling, and promotional material for these devices. That warning statement must read:
[76 FR 16294, Mar. 23, 2011, as amended at 76 FR 82131, Dec. 30, 2011]
[Federal Register Volume 75, Number 8 (Wednesday, January 13, 2010)]
[Notices]
[Pages 1799-1800]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-439]


-----------------------------------------------------------------------

DEPARTMENT OF HOMELAND SECURITY

Coast Guard

[Docket No. USCG-2009-0299]


Terminate Long Range Aids to Navigation (Loran-C) Signal

AGENCY: U.S. Coast Guard, DHS.

ACTION: Notice; correction.

-----------------------------------------------------------------------

SUMMARY: The Coast Guard is correcting a notice that appeared in the 
Federal Register of January 7, 2010 (75 FR 998). The document announced 
termination of the Long Range Aids to Navigation (Loran-C) Signal 
commencing on or about February 8, 2010. The document had an incorrect 
word in the DATES section.

DATES: Effective January 13, 2010.

FOR FURTHER INFORMATION CONTACT: If you have questions on this notice, 
contact Mr. Mike Sollosi, U.S. Coast Guard, Department of Homeland 
Security, telephone (202) 372-1545, <a href="/cdn-cgi/l/email-protection#f9b490929cd7b4d7aa969595968a90b98c8a9a9ed7949095"><span class="__cf_email__" data-cfemail="80cde9ebe5aecdaed3efececeff3e9c0f5f3e3e7aeede9ec">[email protected]</span></a>.

SUPPLEMENTARY INFORMATION: In the Federal Register of January 7, 2010, 
in

[[Page 1800]]

FR Doc. 2010-83, on page 998 in the second column under DATES, correct 
``Transmission of the Loran-C signal and phased decommissioning of the 
Loran-C infrastructure will commence on or about February 8, 2010'' to 
read: ``Termination of the Loran-C signal and phased decommissioning of 
the Loran-C infrastructure will commence on or about February 8, 
2010.''

    Dated: January 7, 2010.
Mark W. Skolnicki,
Commander, U.S. Coast Guard, Acting Chief, Office of Regulations and 
Administrative Law.
[FR Doc. 2010-439 Filed 1-12-10; 8:45 am]
BILLING CODE 9110-04-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
11TH COURT OF APPEALS

EASTLAND, TEXAS

JUDGMENT

In the matter of Craig White, * From the 132nd District Court

a vexatious litigant, of Scurry County,

 Trial Court No. 1-2022

No. 11-22-00077-CV * May 19, 2022

* Per Curiam Memorandum Opinion

 (Panel consists of: Bailey, C.J.,

Trotter, J., and Williams, J.)

This court has inspected the record in this cause and concludes that the appeal 

should be dismissed for want of jurisdiction. Therefore, in accordance with this 

court’s opinion, the appeal is dismissed. The costs incurred by reason of this 

appeal are taxed against Craig White.
#### D. H. R. Construction Company, Inc. *v.*Charles G. Karanian et al.

*Lester Katz,*for the appellee (plaintiff).

*Elliott B. Pollack,*for the appellants (defendants).

Argued October 7

decided October 7, 1969

The motion by the plaintiff to dismiss the appeal from the Court of Common Pleas in Hartford County is granted.
Exhibit 24

                                POWER OF ATTORNEY

      The  undersigned  hereby  constitutes  and appoints  Morton A. Plawner and
James T. Foran, and each of them (with full power to act without the other), the
true and lawful attorney-in-fact and agent for and on behalf of the undersigned,
and in the undersigned's name, place and stead, in the undersigned's capacity as
a Director or Officer or both, as the case may be, of PSEG Power LLC  ("Power"),
PSEG Fossil  LLC,  PSEG  Nuclear  LLC and/or  PSEG Energy  Resources & Trade LLC
(together,  the "Registrants") to sign the Registration Statement on Form S-4 to
be filed by the Registrants with the Securities and Exchange  Commission for the
registration  under  the  Securities  Act  of  1933  of  $500,000,000  aggregate
principal amount of Power's 67/8% Senior Notes due 2006,  $800,000,000 aggregate
principal  amount  of  Power's  73/4%  Senior  Notes  due 2011 and  $500,000,000
aggregate  principal  amount of Power's 85/8% Senior Notes due 2031, and any and
all amendments of such Registration Statement.

      IN WITNESS WHEREOF,  each of the undersigned has executed this instrument,
this 10th day of September, 2001.

           /s/ E. James Ferland                      /s/ Frank Cassidy
         -------------------------              ----------------------------
             E. James Ferland                          Frank Cassidy




           /s/ Harold W. Keiser                   /s/ Steven R. Teitelman
         -------------------------              ----------------------------
             Harold W. Keiser                         Steven R. Teitelman




           /s/ Patricia A. Rado                     /s/ Thomas R. Smith
         -------------------------              ----------------------------
             Patricia A. Rado                           Thomas R. Smith




                                                  /s/ Robert J. Dougherty, Jr.
                                                ----------------------------
                                                      Robert J. Dougherty, Jr.




           /s/ R. Edwin Selover                   /s/ Michael J. Thomson
         -------------------------              ----------------------------
             R. Edwin Selover                        Michael J. Thomson




           /s/ Robert C. Murray                    /s/ Thomas M. O'Flynn
         -------------------------              ----------------------------
             Robert C. Murray                         Thomas M. O'Flynn
# C_2015065EN.01002101.xml

| 23.2.2015 | EN | Official Journal of the European Union | C 65/21 |
| --- | --- | --- | --- |

23.2.2015

EN

Official Journal of the European Union

C 65/21

---

Request for a preliminary ruling from the Hoge Raad der Nederlanden (Netherlands) lodged on 24 November 2014 — Toorank Productions BV v Staatssecretaris van Financiën

(Case C-532/14)

(2015/C 065/31)

Language of the case: Dutch

Referring court

Referring court

Hoge Raad der Nederlanden

Parties to the main proceedings

Parties to the main proceedings

Applicant: Toorank Productions BV

Applicant:

Defendant: Staatssecretaris van Financiën

Defendant:

Question referred

Question referred

Should heading 2206 of the CN be interpreted as meaning that a beverage with an alcoholic strength by volume of 13,4 % vol, obtained by mixing a purified, alcoholic beverage (base) known as ‘Ferm Fruit’, obtained by fermentation from apple concentrate, with sugar, aromatic substances, colouring and flavouring agents, thickening agents, preservatives and distilled alcohol — in the sense that that alcohol does not exceed, either in volume or in percentage, 49 per cent of the alcohol occurring in the beverage, whereas 51 per cent thereof consists of alcohol obtained by fermentation — should be classified under that heading? If not, should subheading 2208 70 of the CN be interpreted as meaning that a beverage such as that should be classified as liqueur under that subheading?

---
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.1225 Creatinine test system. ( a ) *Identification.* A creatinine test system is a device intended to measure creatinine levels in plasma and urine. Creatinine measurements are used in the diagnosis and treatment of renal diseases, in monitoring renal dialysis, and as a calculation basis for measuring other urine analytes.
( b ) *Classification.* Class II.
# C_2014372EN.01000402.xml

| 20.10.2014 | EN | Official Journal of the European Union | C 372/4 |
| --- | --- | --- | --- |

20.10.2014

EN

Official Journal of the European Union

C 372/4

---

Request for a preliminary ruling from the Cour administrative d’appel de Versailles (France) lodged on 13 August 2014 — Groupe Steria SCA v Ministry of Finance and Public Accounts

(Case C-386/14)

2014/C 372/07

Language of the case: French

Referring court

Referring court

Cour administrative d’appel de Versailles

Parties to the main proceedings

Parties to the main proceedings

Applicant: Groupe Steria SCA

Applicant:

Defendant: Ministry of Finance and Public Accounts

Defendant:

Question referred

Question referred

Must Article 43 EC (now Article 49 TFEU) on freedom of establishment be interpreted as precluding the rules governing the French tax-integration regime from granting a tax-integrated parent company neutralisation as regards the add-back of the proportion of costs and expenses, fixed at 5 % of the net amount of the dividends received by it from tax-integrated resident companies only, when such a right is refused to it under those rules as regards the dividends distributed to it from its subsidiaries established in another Member State, which had they been resident would have been eligible in practice, if they so elected?

---
Exhibit 32.2


CERTIFICATION PURSUANT TO


18 U.S.C. SECTIONS 1350,


AS ADOPTED PURSUANT TO


SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002





In connection with the Quarterly Report on Form 10-Q of Ebix, Inc. (the “Company”) for the period ended September 30, 2010 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Robin Raina, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to 906 of the Sarbanes-Oxley Act of 2002, that:





1. The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and


2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


By:/s/ Robert KerrisName: Robert KerrisChief Financial Officer


August 9, 2011
§ 582.5994 Zinc stearate. ( a ) *Product.* Zinc stearate prepared from stearic acid free from chick-edema factor.
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.
**Exhibit 32.1**

 

**CERTIFICATION PURSUANT TO**

 

**18 U.S.C. SECTION 1350,**

 

**AS ADOPTED PURSUANT TO**

 

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

 

In connectionwith the Quarterly Report on Form 10-Q of Ebix, Inc. (the “Company”) for thequarterly period ended June 30, 2004, as filed with the Securities and ExchangeCommission on the date hereof (the “Report”), I, Robin Raina, Chief ExecutiveOfficer of the Company, certify, pursuant to 18 U.S.C. 1350, as adoptedpursuant to 906 of the Sarbanes-Oxley Act of 2002, that:

 

1. The Report fully complieswith the requirements of section 13(a) or 15(d) of the Securities Exchange Actof 1934; and

 

2. The information contained inthe Report fairly presents, in all material respects, the financial conditionand results of operations of the Company.

 

 
| By:                      | /s/ Robin  Raina |   |
|--------------------------|------------------|--------|
|                     |             |
| Name:                    | Robin Raina      |   |
|                     |             |
| Chief  Executive Officer |             |
|                     |             |
| August 16,  2004         |             |
|                          |                  |        |  |

 

1

----
EX-31
     RULE 13a-14(a)/15d-14(a) CERTIFICATION OF EDWARD H. WEBB

            RULE 13a-14(a)/15d-14(a) CERTIFICATION

I, Edward H. Webb, President, certify that:

1.  I have reviewed this quarterly report on Form 10-QSB of W-J
International, Ltd.;

2.  Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances
under which such statements were made, not misleading with respect to
the period covered by this report;

3.  Based on my knowledge, the financial statements, and other
financial information included in this report, fairly present in all
material respects the financial condition, results of operations and
cash flows of the small business issuer as of, and for, the periods
presented in this report;

4.  I am responsible for establishing and maintaining disclosure
controls and procedures (as defined in Exchange Act Rules 13a-15(e)
and 15d-15(e)) [omitted pursuant to extended compliance period] for
the small business issuer and have:

(a) Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the
small business issuer, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly
during the period in which this report is being prepared;

(b)  [omitted pursuant to extended compliance period]

(c) Evaluated the effectiveness of the small business issuer's
disclosure controls and procedures and presented in this report
our conclusions about the effectiveness of the disclosure
controls and procedures, as of the end of the period covered by
this report based on such evaluation; and

(d) Disclosed in this report any change in the small business
issuer's internal control over financial reporting that occurred
during the small business issuer's most recent fiscal quarter
(the small business issuer's fourth fiscal quarter in the case of
an annual report) that has materially affected, or is reasonably
likely to materially affect, the small business issuer's internal
control over financial reporting; and

5.  I have disclosed, based on my most recent evaluation of internal
control over financial reporting, to the small business issuer's
auditors and the audit committee of the small business issuer's board
of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the
design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the small
business issuer's ability to record, process, summarize and
report financial information; and

(b) Any fraud, whether or not material, that involves management
or other employees who have a significant role in the small
business issuer's internal control over financial reporting.


Dated: May 11, 2004                    By: /s/  Edward H. Webb
                                       Edward H. Webb, President